Abstract
For several decades, combination chemotherapy has been used in the treatment of extensive stages of small cell lung cancer (SCLC), and despite the initial response, the median survival was only 8-10 months. Improvement in SCLC treatment has been achieved using combinations of immunooncological treatment with chemotherapy (PD-L1 inhibitor durvalumab in combination with etoposide + cis/carboplatin), as evidenced by the results of the CASPIAN study.
This treatment has been approved h E..-::>: : September 1, 2020. Similar results were obtained in the IMpower133 study using the combination of atezolizumab with etoposide and carboplatin.
This paper summarses theoretical assumptions for better effectiveness of such combined treatment as well as arguments why it is less advantageous to book immunooncological treatment onl> after the failure of previous chemotherapy. The combination of immunooncological treatment and chemotherapy, SoC as the combination of the PD-L1 inhibitor durvalumab and etoposide with cis/carboplatin, should soon become the standard of care for patients with extensive SCLC in the Czech Republic.